Lexology January 18, 2025
Duane Morris LLP

On January 17, 2025, the U.S. Drug Enforcement Administration (DEA) issued a Notice of Proposed Rulemaking (Notice) to allow for remote prescription of certain controlled substances within the telemedicine exception provided by the Ryan Haight Act (Act). The Act generally prohibits prescribing drugs without at least one “in-person medical evaluation” with a healthcare provider, but it excepts from this requirement providers “engaged in the practice of telemedicine.” During the COVID-19 public health emergency, DEA used this telemedicine exception to allow providers to tele-prescribe Schedule II-V controlled substances, implementing temporary flexibilities to that effect via a March 25, 2020, letter and a March 31, 2020, letter. DEA, the Department of Health and Human Services and the Substance Abuse and Mental Health...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Digital Health, Govt Agencies, Provider, Technology, Telehealth
Are third-party telehealth prescriptions of GLP-1s safe?
Unifying telemedicine efforts can help health systems succeed with virtual care
Telehealth For Menopause: Shifting Care Norms And Expanding Access
Communicating with your doctor online could cost you
Iris Telehealth Acquires innovaTel to Expand Telepsychiatry Services

Share This Article